66635-93-6

Basic information

• Product Name: (R)-(+)-Ketorolac
• Synonyms: Ketorolac R-IsoMer;(1R)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid;(R)-(+)-Ketorolac;(R)-Ketorolac
• CAS NO: 66635-93-6
• Molecular Formula: C₁₅H₁₃NO₃
• Molecular Weight: 255.26862
• Product Categories: Aromatics;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 66635-93-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 163-170°C
• Boiling Point: 493.2°Cat760mmHg
• Flash Point: 252.1°C
• Appearance: /
• Density: 1.33g/cm³
• Vapor Pressure: 1.52E-10mmHg at 25°C
• Refractive Index: 1.659
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (R)-(+)-Ketorolac(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-Ketorolac(66635-93-6)
• EPA Substance Registry System: (R)-(+)-Ketorolac(66635-93-6)

Safety Data

• Hazardous Substances Data: 66635-93-6(Hazardous Substances Data)

Usage

Description

(R)-(+)-Ketorolac, also known as the R-enantiomer of Ketorolac, is a chiral molecule that plays a significant role in the pharmaceutical industry due to its unique properties. It is one of the two enantiomers of Ketorolac, with the (S)-enantiomer being approximately 60 times more potent. As a prostaglandin biosynthesis inhibitor, (R)-(+)-Ketorolac exhibits analgesic and anti-inflammatory effects, making it a valuable compound for various medical applications.

Uses

Used in Pharmaceutical Industry:
(R)-(+)-Ketorolac is used as an analgesic and anti-inflammatory agent for the management of mild to moderate pain and inflammation. Its role in prostaglandin biosynthesis inhibition helps in reducing pain and inflammation, providing relief to patients.
Used in Research and Development:
In the field of research and development, (R)-(+)-Ketorolac serves as a valuable compound for studying the differences between enantiomers and their effects on biological systems. This knowledge can be applied to develop more effective and safer drugs by understanding the specific actions of each enantiomer.
Used in Drug Formulation:
(R)-(+)-Ketorolac is used in the formulation of various pharmaceutical products, such as tablets, injections, and topical formulations. Its inclusion in these formulations helps in providing targeted pain relief and reducing inflammation, improving the overall efficacy of the treatment.
Used in Comparative Studies:
In comparative studies, (R)-(+)-Ketorolac is used to evaluate the potency and efficacy of the (S)-enantiomer and other related compounds. This helps in understanding the differences in their therapeutic effects and side effects, leading to the development of more effective and safer drugs.

Biochem/physiol Actions

R-Ketorolac is potent and selective Rho-family GTPases Cdc42 (cell division control protein 42) and Rac1 (Ras-related C3 botulinum toxin substrate 1) allosteric inhibitor that modulates downstream GTPase-dependent physiologic responses critical to tumor metastasis. R-ketorolac significantly inhibits ovarian cancer cell adhesion, migration, and invasion.

InChI:InChI=1/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)/t11-/m1/s1

Upstream product

• 74103-06-3 Ketorolac 
• 108061-03-6 ketorolac acid ethyl ester 
• 78-83-1 2-methyl-propan-1-ol 
• 112-30-1 1-Decanol 
• 112-72-1 1-Tetradecanol 
• 71-36-3 butan-1-ol 
• 111-27-3 hexan-1-ol 
• 376628-29-4 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid butyl ester 
• 98-88-4 benzoyl chloride 
• 67-56-1 methanol 
• 80965-09-9 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid methyl ester 

Relevant articles and documents

Dual Mechanoenzymatic Kinetic Resolution of (±)-Ketorolac

Recently, biocatalysis mediated by mechanical energy has become a convenient strategy to obtain highly valuable products following the principles of green chemistry. In particular, mechanoenzymatic techniques have allowed the isolation of chiral drugs wit

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.